CompletedNCT02818777
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
Medication studyAges 40–80United StatesSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 40 years to 80 years.
- Listed locations
- AuroraSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: October 2016
- Recruitment status
- Completed
- Enrollment listed in the registry
- 13
- Sponsor
- University of Colorado, Denver
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 40 Years to 80 Years
- Official registry ID
- NCT02818777
- Official title
Show the full official title
A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease
Get this study by email
Recruitment & locations
CompletedAurora
Questions about this study
Who is behind this study?
The study sponsor is University of Colorado, Denver, a university.
Did this study involve medication?
Yes. The study involved medication, including cannabidiol.
Who was this study for?
Listed age limits: 40 years to 80 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Injections Compared With Oral Medication for Schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia